Early career? The first years of research or practice are, arguably, the most important. It’s when experience and confidence develop, specialist interests flourish, and professional identity takes shape. It’s also a time of challenge. At The Lancet Group, we are committed to strengthening our engagement with early-career clinicians and academics. Our new Clinical Rounds section has been re-developed with this in mind. We strongly encourage medical students, doctors in training, and others in their early career to contribute to our initiatives. Learn how you can get involved: http://spkl.io/60477yRO7
About us
The Lancet was founded in 1823 by Thomas Wakley and began as an independent, international weekly general medical journal. Since then, The Lancet has sought to address urgent topics, initiate debate, put science into context, and influence decision-makers worldwide. Evolving as a group of health and medical journals, we retain the belief that the best science must lead to better lives. Visit our website to learn more.
- Website
-
http://www.thelancet.com
External link for The Lancet Group
- Industry
- Book and Periodical Publishing
- Company size
- 201-500 employees
- Headquarters
- London
- Type
- Public Company
- Founded
- 1823
- Specialties
- publishing
Employees at The Lancet Group
View 353 employees at The Lancet Group
or
Locations
-
Primary
Get directions
125 London Wall
London, EC2Y 5AS, GB
Updates
-
Congratulations to the winners of the first The Elsevier Foundation-Lancet Evidence to Impact Awards, recognising implementation science research that's changing outcomes in Tanzania, Sierra Leone, and Australia.
The inaugural The Lancet Group–Elsevier Foundation Evidence to Impact Awards have found their first winners, and the work they've done is extraordinary. 🇹🇿 In Tanzania, Essential Emergency and Critical Care coverage rose from 33% to 77% after 1,000+ healthcare providers were trained, with a 32% reduction in inpatient mortality – thanks to the effort of a dedicated team at Muhimbili University of Health and Allied Sciences (MUHAS). 🇸🇱 In Sierra Leone, 2YoungLives reduced maternal and perinatal mortality by 48% among adolescent girls – a group disproportionately excluded from traditional care. 🇦🇺 Across rural Australia, the ECORRA Trial led by Deakin University is co-designing context-specific solutions to address a geographic survival gap of up to 72% and will embed these into a network of rural health services to drive equitable cancer care. Congratulations to all three winning teams! Learn more at: http://spkl.io/60457yO0X #ImplementationScience #HealthEquity #GlobalHealth #InclusiveHealth
-
-
The Lancet Group reposted this
🧠Being presented at #AAIC26 the results of the LatAm FINGERS published in the lancet https://lnkd.in/eFmBpn_V 📰Read also the linked comment https://lnkd.in/eyk7Qj5D Amazing effort from and for Latinoamérica
-
-
The Lancet Group reposted this
Women have unique presentations and consequences of haematological disorders, including anaemia, undiagnosed and undertreated bleeding disorders, and hormone-related thrombosis and bleeding❗ 📢A new The Lancet Haematology Commission looks at what can be done! ⚠️ Many disparities between males and females begin in adolescence, with heavy menstrual bleeding the first sign of a bleeding disorder, but most females are not screened for these diseases. A 16-year mean diagnostic delay vs men with bleeding disorders begins here. 🫄 In the reproductive years, the prevalence of anaemia is 4x higher in women than in men. Pregnant women are at risk of many preventable and treatable haematological conditions, including iron-deficiency anaemia, VTE, and obstetric haemorrhage. 🩸Post-partum haemorrhage is the leading cause of post-partum mortality. During perimenopause, women are at continued risk of erratic and heavy menstrual bleeding, and the lack of low- or no-clot-risk hormonal therapies limits treatment options for some women during menopause. 💡To address these many issues, the Commission sets out ten recommendations for regulators, international health bodies, professional societies, funders, and governments. 🔍Explore the full Commission and related articles here: https://lnkd.in/d-y7Y25a International Society on Thrombosis and Haemostasis (ISTH)
-
-
The 2020 WHO–UNICEF–Lancet Commission called for children's voices at the centre of all policy. Five years on, Children in All Policies 2030 reports back: eight lessons on what works—and what still stands in the way. “For too long, political and policy-making paradigms have abruptly dismissed the rights and perspectives of children and future generations”, say the authors. Read more: http://spkl.io/60407HmU0
-
-
❓ Missed the live session? Our webinar on publishing excellence with The Lancet Regional Health – Eastern Mediterranean is now available to watch on-demand. Join Chief Editor Sarah Aleyan, PhD and Senior Editor Esraa Aly, as they walk you through: ✔️ The aims and scope of the journal ✔️ What they're looking for in submissions ✔️ How to best prepare your manuscript for publication in their journal As a gold open access journal, we are committed to advancing clinical practice and health policy in the Eastern Mediterranean with the goal of improving health outcomes for all people regionally and globally. ▶️ Watch on-demand now: https://hubs.li/Q04mFJSM0 #MedicalPublishing #LancetWebinar
-
The Lancet Group reposted this
Proud to present our very special July issue, dedicated to Patient-Centred Reproductive Medicine. Alongside an exciting collection of original research and Reviews, this issue also features thought-provoking Comments and has already generated extensive media coverage. Huge thanks to my colleagues Ben Burwood Sarah Passey, Hannah Taylor Lewis, reviewers and authors for your contributions A few months back, #WHO issued its first-ever guideline on infertility containing good practice statements, strong recommendations, and conditional recommendations. The guideline highlights the necessity to shift focus from costly diagnosis and treatment to prevention for the general population and those at risk. Our Perspective piece focuses on prevention, diagnosis and treatment`. At the same time, the guideline calls for political support and a rights-based approach to implementation, supported by appropriate policy, regulation, and financing, to help individuals achieve their reproductive goals safely. https://lnkd.in/eAEfmnfA A fantastic news piece by Udani Samarasekera on Concerns over reproductive rights as pronatalism increases: https://lnkd.in/eVcj5pRg Measuring what trials miss: decision modelling for value-based reproductive health https://lnkd.in/eEa8u-nU Reimagining reproductive medicine in the age of AI https://lnkd.in/e3BQ2cJS Press coverage: Most IVF ‘add-on’ treatments have no effect on fertility or remain unproven, study says | IVF | The Guardian: https://lnkd.in/gy22hpsT treatments-have-no-effect-on-fertility Services Sold to Boost I.V.F. Odds Backed by Little Evidence, Study Finds - The New York Times https://lnkd.in/g8qs3dmQ Most ‘add-on’ IVF treatments offer ‘false hope’ and do not improve fertility, study says-INDEPENDENT https://lnkd.in/gHbK_wuu IVF add-ons review: Most fertility treatment extras lack evidence, Lancet study finds - India Today https://lnkd.in/gW9vyAGQ IVF add-ons lack scientific evidence for increasing live birth rates: University of Melbourne study
Infertility affects approximately one in six couples worldwide. Since the birth of Louise Brown in 1978, via in vitro fertilisation (IVF), 13 million babies have been born via assisted reproductive technology cycles. But the rise of IVF add-ons has become one of the most pressing issues in fertility medicine. ESHRE’s 2023 Good Practice Recommendations reported that most add-ons did not have sufficient evidence for routine clinical use. “Every individual who enters a fertility clinic arrives as a whole person—with their own history and sense of what success means. Personalised, patient-centred, and empowered care is not an aspiration; it is the standard that every patient deserves.” – The Lancet Obstetrics, Gynaecology, & Women’s Health. Find out more in a special issue: http://spkl.io/60457H8zU
-
-
Infertility affects approximately one in six couples worldwide. Since the birth of Louise Brown in 1978, via in vitro fertilisation (IVF), 13 million babies have been born via assisted reproductive technology cycles. But the rise of IVF add-ons has become one of the most pressing issues in fertility medicine. ESHRE’s 2023 Good Practice Recommendations reported that most add-ons did not have sufficient evidence for routine clinical use. “Every individual who enters a fertility clinic arrives as a whole person—with their own history and sense of what success means. Personalised, patient-centred, and empowered care is not an aspiration; it is the standard that every patient deserves.” – The Lancet Obstetrics, Gynaecology, & Women’s Health. Find out more in a special issue: http://spkl.io/60457H8zU
-
-
The Lancet Group reposted this
🔬 Advancing the future of cancer prevention As part of the Lecture Series on Cancer Breakthroughs, Gustave Roussy and The Lancet Group are pleased to welcome a distinguished international expert: 🎤 Prof. Timothy Rebbeck Harvard T.H. Chan School of Public Health Dana-Farber Cancer Institute 📅 Friday, 18 September 2026 🕔 5 PM (CEST) 📍 Paris (in person) & online This session will explore how precision approaches are transforming cancer prevention and shaping the future of care. 👉 Join us for this exclusive lecture with a Harvard leader in the field. Will you attend in Paris or online? 🌐 https://lnkd.in/euGNzMMf
-
-
🌟 2026 is The Lancet Group’s most successful year on record. 🏆 The Lancet is now ranked the world’s #1 general medical journal in both Journal Impact Factor (109·0, 2025 Journal Citation Reports, Clarivate 2026) and Scopus CiteScore (92·4). No other general medical journal comes close. Across the Group, 22 of 24 titles rank in the top 10 of their JCR subject categories. 16 are in the top 3. Five are #1. 18 have grown their Impact Factors while Lancet journals rank #1 in 15 CiteScore categories. One Group with a shared standard. The best science for better lives. None of this happens without the researchers who trust us with their most important work and the peer reviewers who give their time and expertise to uphold our standards. Behind every paper is a community—and we are grateful to every one of you. Together, we are advancing the best science for better lives. For researchers ready to share their next breakthrough with the world, The Lancet offers: ⚡ Fast track peer review within 72 hours and publication online within four weeks—for eligible #RCTs and original clinical research submitted to The Lancet—without compromising the rigour your work deserves. 🎤 Simultaneous conference publication—The Lancet Group can turn your presentation into a worldwide moment, with promotion through Lancet Conference Alerts, our conference repository on http://spkl.io/604171C4z, and scope for wider media and digital outreach. 📢 Unmatched global reach—The Lancet Group reaches millions of clinicians, researchers, and policymakers across every region, accessible via http://spkl.io/604171C4z and ScienceDirect as well as Elsevier’s innovative AI tools, LeapSpace and ClinicalKey AI. If your research has the potential to change clinical practice and advance the health of people worldwide, The Lancet is where it belongs. ➡️ Submit your next clinical breakthrough to The Lancet: http://spkl.io/604271C4M #ClinicalTrials #ClinicalResearch #MedicalResearch #AcademicMedicine
-
